共刺激阻断与实体器官移植:过去、现在和未来
本文综述了共刺激阻断剂贝拉西普(belatacept)在移植免疫抑制中的发展历程,指出其较钙调神经磷酸酶抑制剂(CNI)方案可提供更优的长期移植物和患者生存,但早期急性细胞性排斥(ACR)风险及给药障碍限制其临床采用;文章还探讨了贝拉西普融入无CNI方案、低剂量他克莫司渐减策略、皮下给药及扩展适应症等未来方向。
要点
- 贝拉西普是首个获批用于移植免疫抑制的共刺激阻断剂,长期移植物和患者生存优于CNI方案。
- 早期ACR风险及给药障碍制约贝拉西普临床推广。
- 低剂量他克莫司渐减联合贝拉西普可兼顾长期获益并降低早期ACR风险。
核心结论
- 贝拉西普较传统CNI方案提供更优的长期肾移植和患者生存,但早期ACR风险及给药障碍影响其临床采用。
- 通过低剂量他克莫司渐减、皮下给药等策略可望扩大贝拉西普的临床应用。
研究设计与样本
- 本文为综述,回顾贝拉西普临床开发历史及BENEFIT和BENEFIT-EXT关键试验结果。
- 综述还纳入近期贝拉西普融入新型无CNI方案的研究及Emory移植中心使用低剂量他克莫司渐减的经验。
主要发现
- 超过10年研究显示贝拉西普较传统CNI方案提供更优的长期肾移植和患者生存。
- 贝拉西普临床采用滞后,因担忧早期ACR风险及多种给药后勤障碍。
- Emory移植中心采用低剂量他克莫司渐减联合贝拉西普,旨在获取长期获益而不增加短期ACR风险。
临床怎么用
- 可考虑将贝拉西普用于肾移植受者以改善长期结局,但需关注早期ACR风险。
- 采用低剂量他克莫司渐减联合贝拉西普可能平衡早期排斥与长期获益。
- 皮下给药或延长给药间隔可能克服贝拉西普给药后勤障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Belatacept is the first costimulatory blockade agent clinically approved for transplant immunosuppression. Although more than 10 years of study have demonstrated that belatacept offers superior long-term renal allograft and patient survival compared to conventional calcineurin inhibitor (CNI)-based immunosuppression regimens, the clinical adoption of belatacept has continued to lag because of concerns of an early risk of acute cellular rejection (ACR) and various logistical barriers to its administration. In this review, the history of the clinical development of belatacept is examined, along with the findings of the seminal BENEFIT and BENEFIT-EXT trials culminating in the clinical approval of belatacept. Recent efforts to incorporate belatacept into novel CNI-free immunosuppression regimens are reviewed, as well as the experience of the Emory Transplant Center in using a tapered course of low-dose tacrolimus in belatacept-treated renal allograft patients to garner the long-term outcome benefits of belatacept without the short-term increased risks of ACR. Potential avenues to increase the clinical adoption of belatacept in the future are explored, including surmounting the logistical barriers of belatacept administration through subcutaneous administration or more infrequent belatacept dosing. In addition, belatacept conversion strategies and potential expanded clinical indications of belatacept are discussed for pediatric transplant recipients, extrarenal transplant recipients, treatment of antibody-mediated rejection (AMR), and in patients with failed renal allografts. Finally, we discuss the novel immunosuppressive drugs currently in the development pipeline that may aid in the expansion of costimulation blockade utilization.
引用
- Kitchens WH, Larsen CP, Badell IR, et al. Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future. Kidney Int Rep. 2023. PMID: 38106575. doi:10.1016/j.ekir.2023.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。